Outcomes Associated with the use of High Dose Corticosteroids and IL-6 Inhibitors for the Treatment of Acute Respiratory Distress Syndrome Secondary to SARS COV-2.

Outcomes Associated with the use of High Dose Corticosteroids and IL-6 Inhibitors for the Treatment of Acute Respiratory Distress Syndrome Secondary to SARS COV-2.

Publication date: Oct 21, 2024

During the COVID-19 pandemic, treatment strategies evolved rapidly. The RECOVERY trial established corticosteroids as the standard care for reducing mortality in COVID-19 patients. However, some critical care clinicians began using doses higher than those recommended in RECOVERY. To characterize the use of high-dose corticosteroids and IL-6 inhibitors in critically ill COVID-19 patients and examine their association with adverse drug events (ADEs). A retrospective cohort study of 320 electronic health records (January 1, 2020 – June 30, 2022) was conducted on COVID-19 patients requiring high-flow oxygen or mechanical ventilation. Patients were categorized based on corticosteroid dose: “high dose dexamethasone” (daily dose greater than 12 mg and/or for longer than 10 days), “low dose dexamethasone” (daily dose 12 mg or less for 10 days or less), and “no dexamethasone” (no corticosteroid therapy). Subgroups were created based on IL-6 inhibitor use. High-dose dexamethasone was associated with increased odds of ADEs compared to low dose (OR 2. 55, 95% CI 1. 45 to 4. 49) and no dexamethasone (OR 6. 29, 95% CI 2. 08 to 19. 03). No additional efficacy benefit was observed in patients receiving high dose corticosteroids when compared to low dose corticosteroids. Patients receiving both an IL-6 inhibitor and high-dose dexamethasone had further increased odds of ADEs. High-dose dexamethasone was also associated with increased mortality compared to low dose (OR 3. 78, 95% CI 1. 97-7. 25) and no dexamethasone (OR 15. 22, 95% CI 3. 27-70. 74). Acknowledging the risk for residual confounding, higher doses of dexamethasone were associated with increased ADEs and mortality. These findings highlight the need for careful consideration of the use of high-dose dexamethasone.

Concepts Keywords
Higher COVID-19
June dexamethasone
Pandemic IL-6 inhibitor
Therapy tocilizumab

Semantics

Type Source Name
disease MESH Acute Respiratory Distress Syndrome
disease MESH COVID-19 pandemic
disease MESH critically ill
disease MESH adverse drug events
drug DRUGBANK Oxygen
drug DRUGBANK Dexamethasone
drug DRUGBANK Tocilizumab

Original Article

(Visited 1 times, 1 visits today)